Goldman Sachs upgraded Cytokinetics Inc (CYTK) to Buy from Neutral on December 18, 2025. The stock is currently priced at $69.87.
This upgrade reflects a more optimistic view on the company's prospects, suggesting improved fundamentals or better-than-expected performance. Analyst ratings often provide valuable insights based on research and financial models, but they should be considered alongside other factors such as company fundamentals and industry trends.
Cytokinetics, based in South San Francisco, California, focuses on developing muscle activators and inhibitors for treating diseases that compromise muscle performance. The company has a market cap of $7.6 billion and an EPS of -6.31. Upcoming earnings are scheduled for May 4, 2026, with an estimated EPS of -1.67 and revenue of $13.8 million.
As of December 1, 2025, the analyst consensus for Cytokinetics is a Buy, with 5 Strong Buy, 16 Buy, and 5 Hold ratings among a total of 26 analysts. Recent analyst actions include a reiteration of Buy from Needham and an upgrade to Buy from Goldman Sachs.
Investors should remember that analyst ratings can change as new information becomes available. They represent one of many inputs to consider when making investment decisions.